A stark contrast is emerging within Ireland’s healthcare system: while clinical research activity is experiencing promising growth, patients suffering from rare diseases are facing increasingly severe delays in accessing newly approved treatments. Recent data from the Irish Pharmaceutical Healthcare Association (IPHA) reveals that patients in Ireland now wait an average of 801 days to access rare disease medicines following European regulatory approval.
The Growing Access Gap
The 801-day wait time represents a sharp deterioration from previous years and sits significantly higher than the EU average. Crucially, of the 66 rare disease medicines approved by the European Medicines Agency (EMA) between 2021 and 2024, only 27% are currently reimbursed and publicly available to patients in Ireland. Patient advocacy groups have expressed mounting frustration over structural inefficiencies in the national pricing and reimbursement process that continue to delay life-changing therapies.
Encouraging Clinical Trial Growth
Conversely, the life sciences sector in Ireland is witnessing a notable uptick in clinical research. The IPHA reports that industry-sponsored clinical trials rose from 41 in 2023 to 73 in 2025. This growth signals strong international confidence in Ireland's research capabilities and clinical infrastructure.
However, industry bodies warn that Ireland still lags behind peer nations like Denmark, which initiated more than double the number of clinical trials during the same period. Furthermore, Ireland is currently ranked as the slowest EU member state for regulatory setup times, taking an average of 213 days to ready a clinical trial site.
The Path Forward
While the newly signed Framework Agreements aim to streamline the reimbursement process over the coming years, stakeholders are heavily lobbying for immediate systemic reforms. Achieving faster access to rare disease treatments and streamlining clinical trial activations are widely viewed as critical imperatives to ensure Irish patients do not fall further behind their European counterparts.
Clinical Trial Infrastructure Gaps in Ireland
A joint report by the Irish Pharmaceutical Healthcare Association (IPHA) and rare disease patient groups has highlighted significant structural bottlenecks in Ireland's clinical trial network. Despite having a world-class pharmaceutical manufacturing sector, Ireland lags behind European peers in the initiation and execution of clinical trials for rare disease therapies. The main obstacles include slow ethical review timelines, fragmented hospital data systems, and a lack of dedicated clinical trial coordinators in public hospitals.
Currently, setting up a clinical trial in Ireland can take up to 12 months, compared to under 3 months in countries like Denmark or Belgium. This delay means that Irish patients with rare, life-threatening conditions are missed by global trial enrollments, forcing them to travel abroad to access experimental treatments.
The Path to Reform: National Clinical Trials Office
To address these bottlenecks, the IPHA is advocating for the establishment of a centralized National Clinical Trials Office to streamline approvals, implement standardized contracts across all HSE hospitals, and invest in digital health records. By reducing setup times and improving patient matching, Ireland can double its clinical trial capacity, attracting additional R&D investment and providing immediate, cost-free access to innovative medicines for patients.
Frequently Asked Questions
Why are clinical trials for rare diseases particularly difficult to run?
Rare diseases affect small patient populations scattered globally, making patient recruitment and retention extremely challenging. Any administrative or regulatory delay in setting up a trial site can cause the study to miss its enrollment goals.
How long are the current clinical trial setup times in Ireland?
Setting up a clinical trial in Ireland currently takes an average of 9 to 12 months due to fragmented administrative and ethical review processes across different hospital groups.
What reforms are being proposed to improve clinical trial access in Ireland?
Proposed reforms include centralizing the ethical approval process, standardizing hospital contracts, implementing national digital health records, and funding dedicated clinical research infrastructure within the HSE.
Frequently Asked Questions
Why are rare disease trials particularly slow in Ireland?
Due to the small patient pool, identifying eligible participants is difficult. Additionally, administrative delays in setting up national ethics committees prolong wait times.
What is the IPHA's recommendation to accelerate trials?
The IPHA advocates for centralizing clinical trial contracts, introducing digital consent tools, and expanding funding for dedicated rare disease research networks.
How do trial delays impact Irish patients?
Delays restrict patient access to innovative, life-saving therapies that are already available in other European countries with faster clinical authorization pathways.
Frequently Asked Questions
Why are rare disease trials particularly slow in Ireland?
Due to the small patient pool, identifying eligible participants is difficult. Additionally, administrative delays in setting up national ethics committees prolong wait times.
What is the IPHA's recommendation to accelerate trials?
The IPHA advocates for centralizing clinical trial contracts, introducing digital consent tools, and expanding funding for dedicated rare disease research networks.
How do trial delays impact Irish patients?
Delays restrict patient access to innovative, life-saving therapies that are already available in other European countries with faster clinical authorization pathways.
